Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence.The deal extends ...

Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease. The pharmaceutical giant likes what it’s seen so ...

The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...

Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and ...

Valo Health, Inc is leveraging artificial intelligence (AI) and advanced analytics to better learn from the patient experience to discover and develop better medicines at greater speed and scale.